For more information on Aimovig™, including U.S. prescribing information, please visit www.aimovig.com.
18 May 2018
FDA Announces Approval of Aimovig For Migraine Prevention
Novartis today announced that the US Food and Drug Administration (FDA) has approved Aimovig™ (erenumab-aooe) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to play a critical role in migraine. Aimovig 70 mg is self-administered once monthly via Amgen's device, the SureClick® autoinjector, and does not require a loading dose. Some patients may benefit from a dosage of 140 mg once monthly.
For more information on Aimovig™, including U.S. prescribing information, please visit www.aimovig.com.
For more information on Aimovig™, including U.S. prescribing information, please visit www.aimovig.com.
Subscribe to:
Post Comments
(
Atom
)
No comments :
Post a Comment
Thank you for reading! Comments are welcomed and encouraged. If you have any questions, you can submit them on the Contact Me page.
Stay Well!